305 related articles for article (PubMed ID: 11655388)
1. Universities take to the market place.
Yanchinski S
New Sci; 1981 Dec; 92(1282):675-7. PubMed ID: 11655388
[No Abstract] [Full Text] [Related]
2. Industry funds in universities: new guidelines emerge from Pajaro Dunes.
Dickson D
Nature; 1982 Apr; 296(5856):381-2. PubMed ID: 11643726
[TBL] [Abstract][Full Text] [Related]
3. Commercialization of research: so far.
Aisenberg J
Nature; 1982 Jun 24-30; 297(5868):617. PubMed ID: 11650535
[TBL] [Abstract][Full Text] [Related]
4. University/corporate research agreements.
Hutt PB
Technol Soc; 1983; 5(2):107-18. PubMed ID: 11650686
[No Abstract] [Full Text] [Related]
5. Does biotechnology have a price?
Nature; 1982 Apr; 296(5857):479-80. PubMed ID: 11643737
[No Abstract] [Full Text] [Related]
6. Biotechnology and the commercial use of human cells: toward an organic view of life and technology.
Martin PA; Lagod ML
Santa Clara Comput High Technol Law J; 1989 Jun; 5(2):211-61. PubMed ID: 11659674
[No Abstract] [Full Text] [Related]
7. Pajaro Dunes: the search for consensus.
Culliton BJ
Science; 1982 Apr; 216(4542):155-156, 158. PubMed ID: 11643731
[TBL] [Abstract][Full Text] [Related]
8. Conflicts of interest: tighter controls.
Dickson D
Nature; 1981 Oct; 293(5833):503-504. PubMed ID: 11662009
[No Abstract] [Full Text] [Related]
9. Biotechnology and the social reconstruction of molecular biology.
Markle GE; Robin SS
Sci Technol Human Values; 1985; 10(1):70-9. PubMed ID: 11650692
[No Abstract] [Full Text] [Related]
10. Academic values tested by MIT's new center.
Lepkowski W
Chem Eng News; 1982 Mar; 60(11):7-12. PubMed ID: 11650457
[No Abstract] [Full Text] [Related]
11. The big bucks of biology.
Begley S
Newsweek; 1982 Apr; 99(14):69-70. PubMed ID: 11650514
[No Abstract] [Full Text] [Related]
12. Public policy symposium: the legal, ethical, and economic impact of patient material used for product development in the biomedical industry.
Royston I; Wagner AB; Caplan AL; Rosenberg LE
Clin Res; 1985 Oct; 33(4):442-58. PubMed ID: 11643828
[No Abstract] [Full Text] [Related]
13. Second thoughts about U.S. Patent #4,438,032.
Burrows B
Bull Med Ethics; 1997 Jan; No. 124():11-4. PubMed ID: 11655049
[No Abstract] [Full Text] [Related]
14. The laboratory as profit center.
Tenner E
Harv Mag; 1981; 83(3):15-9. PubMed ID: 11650493
[No Abstract] [Full Text] [Related]
15. Biotechnology, patients' rights, and the Moore case.
Howard JJ
Food Drug Cosmet Law J; 1989 Jul; 44(4):331-58. PubMed ID: 11659209
[No Abstract] [Full Text] [Related]
16. From Asilomar to industrial biotechnology: risks, reductionism and regulation.
Krimsky S
Sci Cult (Lond); 2005 Dec; 14(4):309-23. PubMed ID: 16619467
[No Abstract] [Full Text] [Related]
17. The dirtiest dilemma of all: should university researchers take the tobacco companies' tainted money?
Motluk A
New Sci; 1996 Aug; 151(2045):12-3. PubMed ID: 11656549
[No Abstract] [Full Text] [Related]
18. The DNA disease.
Stetten D
Nature; 1982 May; 297(5864):260. PubMed ID: 11643747
[No Abstract] [Full Text] [Related]
19. Vital research caught in patent crossfire.
Coghlan A
New Sci; 1993 Jan; 137(1857):4. PubMed ID: 11659565
[No Abstract] [Full Text] [Related]
20. Conflicts of interest.
Nature; 1989 Aug; 340(6236):664. PubMed ID: 11644385
[No Abstract] [Full Text] [Related]
[Next] [New Search]
